Vertex Reports Phase 2 Data for Semaglutide in IgA vasculitis

Vertex today announced Phase 2 results for Semaglutide in patients with IgA vasculitis. The study demonstrated that Semaglutide provides durable benefit over long-term follow-up compared to standard of care or placebo. These results provide important insights into the treatment of IgA vasculitis and support the continued development of Semaglutide in this patient population. The data were presented at a major medical conference and will be submitted for publication in a peer-reviewed journal. Regulatory submissions are planned based on these results. The safety profile of Semaglutide was consistent with previous observations, with no new safety signals identified.